本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
AAT announces additional significant updates RADNOR, Pa., Jan. 29, 2025 /PRNewswire/ -- Advanced Aesthetic Technologies, Inc. ("AAT") announced today that their partner in China has obtained approval to market their unique dermal filler Algeness® VL agarose facial injection filler, a 2.5% agarose gel dermal filler. AAT's development and distribution partner is Lanzhou Biotechnique Development Co., Ltd. ("LanDev"), the aesthetic section company of China National Biotec Group Company Limited (belonging to Sinopharm Group, "CNBG"), which acted as the agent for Algeness® VL agarose facial injection filler and obtained the registration license as an imported Class III medical device from the National Medical Products Administration. Algeness® is the first officially approved agarose-based injection filler in China. Algeness® is the culmination of many years of scientific and clinical research to define a novel biocompatible material to fill wrinkles and volume loss in facial soft tissues. Their team of scientists and physicians worked with Algeness® to create an exceptional 100% natural and biodegradable injectable implant with a unique injection technique. According to Doug Abel, President and CEO of AAT, "We are excited and look forward to the entry of Algeness® into the large aesthetic market in China through our partner LanDev. We believe that LanDev is the ideal partner to maximize the success of Algeness® in China as they are the sole domestic Chinese manufacturer of botulinum toxin and their product, Hengli, was the first to launch in China and holds significant market share. This approval marks a significant accomplishment by the LanDev, CNBG, AAT, and Ghimas teams and our regulatory advisors and partners." "We see the upcoming entry into the market in China with such a strong partner as transformational for the Company, and a demonstration of the clinical performance of this truly unique product," he adds. This important achievement follows a series of significant milestones for Advanced Aesthetic Technologies that were reached over the last two years including: Successfully advancing the clinical trial to be submitted to the US FDA as part of the Pre-Market Authorization (PMA process) through the primary safety and efficacy endpoints with additional, ongoing patient follow up. Advancing the balance of the required information for US FDA submission in 2025. Obtaining the CE Mark under the elevated requirements of the Medical Device Regulations (MDR) initially with therapeutic claims and recently expanding the label to include aesthetic claims under Annex XVI. Acquiring a controlling interest in Ghimas, S.p.A., the original developer and manufacturer of Algeness®. Plastic Surgeon Dr. Omer Buhsem from Istanbul serves as the Medical Director for Algeness® and has conducted preclinical work with the product portfolio. "I believe that Algeness®, through its unique rheology and structure, brings an important additional tool to our aesthetic armamentarium from both efficacy and safety perspectives. With my patients, I am uniquely able to define the desired shape while working with a product that I have found to be very safe." Dr. Buhsem has previously published a 700-patient retrospective of his experience with Algeness®. The unique Algeness® dermal filler continues to receive very positive reviews from aesthetic practitioners globally. According to dermatologist Dr. Tatjana Pavicic of Munich, Germany, "Algeness® is a true revolution in the field of aesthetic medicine. It stands out for its purely natural composition, biocompatibility, and the remarkable, natural-looking results we can achieve for our patients. In our nearly 10 years of experience with Algeness®, my patients report high satisfaction with the immediate lift and long-lasting results, and I appreciate the product's excellent safety profile and predictability." The approval in China combined with the Company's achievement of critical milestones launches AAT into the next stage. Future commercialization in China combined with the potential for US approval, the significant product performance data developed to support registration, and the unique product profile provide the foundation for Algeness® to have an important place in medical aesthetics. About Advanced Aesthetic Technologies, Inc. AAT is a fast-growing, global corporation developing new technologies for aesthetic medicine. Their Algeness® family of injectable implants is the culmination of many years of scientific and clinical research with the goal of providing aesthetic treatment providers with advances in the ability to achieve deep structural support, clean definition, and exceptional clinical outcomes where patients receive their outcome at the time of treatment. Algeness® is a 100% natural and biodegradable filler based on purified agarose with a differentiated clinical and safety performance profile. AAT continuously invests in research and product development to expand the scientific knowledge on Algeness® and agarose while continually pursuing new and innovative technologies to expand our portfolio. Algeness® is the all-natural, biodegradable, biocompatible agarose-based gel implant, free of all synthetic or cross-linking chemicals. Algeness® dermal fillers add immediate facial volume with excellent persistence without the cross-linking chemicals found in Hyaluronic Acid fillers. It is currently available in many markets in for concentrations of agarose to match specific cosmetic improvements of the lips, fine lines, naso-labial folds and for shaping the cheeks, jawline and other facial areas. In China, only Algeness® VL agarose facial injection filler is now approved for the treatment of nasolabial folds. As of this release, AAT is in the process of pursuing registration in the U.S. market through the U.S. Food and Drug Administration (FDA). For more information, Algeness.com For media inquiries, Media@algeness.com For more information about Algeness® Dermal Filler: Filler@algeness.com For inquiries about global distribution: Algeness.com/algeness Facebook: Facebook.com/AlgenessInstagram: Instagram.com/Algeness/LinkedIn: https://www.linkedin.com/company/advanced-aesthetic-technologies-inc-algeness/ Advanced Aesthetics Technologies, Inc.150 North Radnor-Chester Road, Suite F-200, Radnor, PA 19087
AAT announces additional significant updates RADNOR, Pa., Jan. 29, 2025 /PRNewswire/ -- Advanced Aesthetic Technologies, Inc. ("AAT") announced today that their partner in China has obtained approval to market their unique dermal filler Algeness® VL agarose facial injection filler, a 2.5% agarose gel dermal filler. AAT's development and distribution partner is Lanzhou Biotechnique Development Co., Ltd. ("LanDev"), the aesthetic section company of China National Biotec Group Company Limited (belonging to Sinopharm Group, "CNBG"), which acted as the agent for Algeness® VL agarose facial injection filler and obtained the registration license as an imported Class III medical device from the National Medical Products Administration. Algeness® is the first officially approved agarose-based injection filler in China. Algeness® is the culmination of many years of scientific and clinical research to define a novel biocompatible material to fill wrinkles and volume loss in facial soft tissues. Their team of scientists and physicians worked with Algeness® to create an exceptional 100% natural and biodegradable injectable implant with a unique injection technique. According to Doug Abel, President and CEO of AAT, "We are excited and look forward to the entry of Algeness® into the large aesthetic market in China through our partner LanDev. We believe that LanDev is the ideal partner to maximize the success of Algeness® in China as they are the sole domestic Chinese manufacturer of botulinum toxin and their product, Hengli, was the first to launch in China and holds significant market share. This approval marks a significant accomplishment by the LanDev, CNBG, AAT, and Ghimas teams and our regulatory advisors and partners." "We see the upcoming entry into the market in China with such a strong partner as transformational for the Company, and a demonstration of the clinical performance of this truly unique product," he adds. This important achievement follows a series of significant milestones for Advanced Aesthetic Technologies that were reached over the last two years including: Successfully advancing the clinical trial to be submitted to the US FDA as part of the Pre-Market Authorization (PMA process) through the primary safety and efficacy endpoints with additional, ongoing patient follow up. Advancing the balance of the required information for US FDA submission in 2025. Obtaining the CE Mark under the elevated requirements of the Medical Device Regulations (MDR) initially with therapeutic claims and recently expanding the label to include aesthetic claims under Annex XVI. Acquiring a controlling interest in Ghimas, S.p.A., the original developer and manufacturer of Algeness®. Plastic Surgeon Dr. Omer Buhsem from Istanbul serves as the Medical Director for Algeness® and has conducted preclinical work with the product portfolio. "I believe that Algeness®, through its unique rheology and structure, brings an important additional tool to our aesthetic armamentarium from both efficacy and safety perspectives. With my patients, I am uniquely able to define the desired shape while working with a product that I have found to be very safe." Dr. Buhsem has previously published a 700-patient retrospective of his experience with Algeness®. The unique Algeness® dermal filler continues to receive very positive reviews from aesthetic practitioners globally. According to dermatologist Dr. Tatjana Pavicic of Munich, Germany, "Algeness® is a true revolution in the field of aesthetic medicine. It stands out for its purely natural composition, biocompatibility, and the remarkable, natural-looking results we can achieve for our patients. In our nearly 10 years of experience with Algeness®, my patients report high satisfaction with the immediate lift and long-lasting results, and I appreciate the product's excellent safety profile and predictability." The approval in China combined with the Company's achievement of critical milestones launches AAT into the next stage. Future commercialization in China combined with the potential for US approval, the significant product performance data developed to support registration, and the unique product profile provide the foundation for Algeness® to have an important place in medical aesthetics. About Advanced Aesthetic Technologies, Inc. AAT is a fast-growing, global corporation developing new technologies for aesthetic medicine. Their Algeness® family of injectable implants is the culmination of many years of scientific and clinical research with the goal of providing aesthetic treatment providers with advances in the ability to achieve deep structural support, clean definition, and exceptional clinical outcomes where patients receive their outcome at the time of treatment. Algeness® is a 100% natural and biodegradable filler based on purified agarose with a differentiated clinical and safety performance profile. AAT continuously invests in research and product development to expand the scientific knowledge on Algeness® and agarose while continually pursuing new and innovative technologies to expand our portfolio. Algeness® is the all-natural, biodegradable, biocompatible agarose-based gel implant, free of all synthetic or cross-linking chemicals. Algeness® dermal fillers add immediate facial volume with excellent persistence without the cross-linking chemicals found in Hyaluronic Acid fillers. It is currently available in many markets in for concentrations of agarose to match specific cosmetic improvements of the lips, fine lines, naso-labial folds and for shaping the cheeks, jawline and other facial areas. In China, only Algeness® VL agarose facial injection filler is now approved for the treatment of nasolabial folds. As of this release, AAT is in the process of pursuing registration in the U.S. market through the U.S. Food and Drug Administration (FDA). For more information, Algeness.com For media inquiries, Media@algeness.com For more information about Algeness® Dermal Filler: Filler@algeness.com For inquiries about global distribution: Algeness.com/algeness Facebook: Facebook.com/AlgenessInstagram: Instagram.com/Algeness/LinkedIn: https://www.linkedin.com/company/advanced-aesthetic-technologies-inc-algeness/ Advanced Aesthetics Technologies, Inc.150 North Radnor-Chester Road, Suite F-200, Radnor, PA 19087 Logo - https://mma.prnasia.com/media2/1517333/algeness_logo_Logo.jpg?p=medium600
The cutting-edge OncoPortal™ Mutation Tracker add-on module enables precision monitoring of evolving genomic cancer drivers BOSTON, MA and ROLLE, Switzerland, Jan. 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has unveiled the OncoPortal™ Mutation Tracker — a longitudinal MRD tracking tool designed for disease monitoring in the context of oncology. This innovation underscores SOPHiA GENETICS' commitment to advancing data-driven approaches for improved oncology insights. Tracking genomic variants across multiple time points in the same patient is becoming increasingly critical in cancer care, particularly for identifying treatment resistance or detecting residual cancer cells, such as in Measurable Residual Disease (MRD) management. The integration of longitudinal tracking capabilities with next-generation sequencing (NGS) allow the parallel detection of cancer-specific genetic mutations at very low frequencies. This combined approach enables early identification of residual disease or emerging variants, providing a more precise assessment of disease burden, better stratification of high-risk patients, and the ability to tailor treatments to the cancer's unique genomic profile. The OncoPortal™ Mutation Tracker augments the SOPHiA DDM™ Platform's core analytical capabilities to allow clinical researchers to longitudinally monitor evolving genomic variants across multiple time points, providing a comprehensive view of disease evolution. The OncoPortal™ Mutation Tracker enhances workflow efficiency for longitudinal variant tracking by offering flexible low frequency variant selection, customizable threshold settings, and reporting features to generate longitudinal graphical representations, simplifying the process of tracking and analyzing genetic changes over time. "The ability to reliably track low frequency variants longitudinally is a game-changer because it allows the detection of even the smallest traces of cancer that can evade traditional methods of testing and ultimately drive relapse," said Philippe Menu, M.D., Ph.D., Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS. "With this new longitudinal tracking capability, we offer a highly customizable, user-friendly solution to enable the generation of novel insights for clinical research. Precise tracking of key genomic variants over time has the potential to eventually enable earlier intervention and more tailored disease management, which may lead to better long-term outcomes for patients." "This longitudinal interface represents the solution we've been seeking to unite our oncologists in embracing broader adoption of NGS. It's the missing piece that unlocks a new frontier in personalized, data-driven medicine," said Dr. Christophe Marzac, Head of the Hematology-Immunology Unit, Gustave Roussy Institute. For more information on the OncoPortal™ Mutation Tracker, visit SOPHiAGENETICS.com. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn. SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. SOPHiA GENETICS Forward-Looking Statements: This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
DUBAI, UAE - Media OutReach Newswire - 28 January 2025 - AstraZeneca, a leading multinational pharmaceutical and biotechnology company, has been recognized as the second-best place to work across the Middle East for 2024 according to the annual prestigious "Best Places to Work" ranking. The company achieved remarkable country-specific ranking in the Best Places to Work certification, including being named the Best Place to Work for Women and the Best Place to Work for Millennials in select markets. AstraZeneca took the top spot in Iraq, Algeria, and Lebanon, while securing second place in Morocco and Tunisia. In Jordan, the company earned the third position. Last year, AstraZeneca ranked second across the Middle East, demonstrating sustained recognition of its workplace culture and reinforcing its position as an employer of choice in the region. In a statement from Rami Scandar, Near East & Maghreb Country President, he said: "It brings me immense pride and gratitude to witness the remarkable achievements that AZ NEMAG consistently attains. With the recent announcement of our rankings as the best places to work, I am delighted to share that we have secured the 1st and 2nd positions in the Middle East. This outstanding accomplishment is a true testament to your hard work, dedication, and commitment to excellence." Heba El Shabrawy, HR Director for AstraZeneca Near East & Maghreb commented on this achievement "Despite the numerous challenges that NEMAG has consistently faced, we continue to be amazed by the incredible talents, commitment, and passion demonstrated by our team members. The achievement of securing the first and second rankings in all our participating markets is a true testament to the remarkable strides we have made over the past year. I would like to take this opportunity to express my gratitude for your hard work and perseverance." AstraZeneca Near East & Maghreb has consistently demonstrated its commitment to fostering a positive and inclusive workplace culture, earning the prestigious Best Place to Work certification for several consecutive years. This achievement reflects the company's dedication to creating an environment where employees feel valued, empowered, and motivated to excel.AstraZeneca Near East & Maghreb excels by prioritizing well-being, growth, and diversity. For more information about AstraZeneca, please visit www.astrazeneca.com. For more information about Best Places to Work certification program, visit www.bestplacestowork.org. Hashtag: #BestPlacesToWorkThe issuer is solely responsible for the content of this announcement.
TOKYO, Jan. 28, 2025 /PRNewswire/ -- ThinkCyte, a biotechnology company pioneering novel artificial intelligence (AI)-based cell analysis and sorting instruments, announced today that it will begin the pre-commercial launch of its new cell analysis platform, VisionCyte™. The announcement coincides with the 2025 Society for Laboratory Automation and Screening (SLAS) conference in San Diego, CA from January 27-30, 2025, where VisionCyte was named a finalist for the 2025 New Product Award. The launch of VisionCyte extends ThinkCyte's product portfolio of life science research platforms beyond VisionSort, the company's flagship product launched in 2023 and adopted by leading biopharmaceutical companies and academic institutions worldwide. The new VisionCyte™ cell analysis platform. The VisionCyte platform leverages high resolution morphological profiling, high-throughput capabilities, and advanced AI analysis to uncover novel biomarkers and facilitate the discovery of new and diversified hits and targets for drug discovery. The full commercial rollout of VisionCyte will occur in 2025, with an initial line of customer ready units available in H2 2025. The company also announced the launch of its Celluminate cell tracking kits, compatible with both VisionSort and VisionCyte, for enabling discovery applications in areas where existing cell surface cell markers are limited such as specific hematological conditions, stem cell research, and age-related diseases. "The expansion of our product portfolio reflects our unwavering commitment to advancing life science research." said Waichiro Katsuda, Chief Executive Officer at ThinkCyte. "By introducing innovative solutions that address the evolving needs of scientists worldwide, we're not just adding products—we're providing the tools to accelerate discoveries in disease understanding and drug discovery to improve lives." More information about the VisionCyte platform can be found by visiting the ThinkCyte booth (#2632) at SLAS 2025 or by visiting thinkcyte.com/visioncyte. About ThinkCyte ThinkCyte, founded in 2016 with offices in Tokyo, Japan and Redwood City, California is a biotechnology company that develops innovative scientific instruments based on integrated, multidisciplinary technologies to enable life science research, diagnostics, and therapeutic development. The company pioneered Ghost Cytometry™, a proprietary AI-based, label-free cell analysis and sorting technology and partners with major global biopharmaceutical companies and leading academic research institutes to drive pioneering research. For more information, please visit www.thinkcyte.com.
The OsmoPRO® MAX Automated Osmometer delivers the automation and data management capabilities required by modern clinical labs. NORWOOD, Mass., Jan. 27, 2025 /PRNewswire/ -- Advanced Instruments, the leading supplier in osmolality testing, announces the newest update to its clinical line of freezing point osmometers. The OsmoPRO® MAX is designed for clinical laboratories of all sizes seeking enhanced productivity through automation. The instrument uses innovative flow-through technology to eliminate manual pipetting and reduce the use of consumables, allowing testing to begin with the single push of a button. OsmoPRO® MAX Automated Osmometer The OsmoPRO MAX goes beyond providing accurate and precise test results to deliver a complete solution that simplifies the osmolality testing workflow. The instrument delivers increased efficiency through direct sampling from primary tubes without transfer to sample cups, automated barcode scanning to reduce transcription errors, and the capability to upload data to the AdvancedQC peer group program for Advanced Instruments' Protinol® and Renol® matrix-based controls. Like all Advanced Instruments osmometers, the OsmoPRO MAX uses the industry-preferred freezing point depression method to deliver reliable osmolality results in minutes. The instrument is automatically cleaned with system fluid after each test to minimize the need for user intervention. New samples can be loaded continuously as they arrive, eliminating the need for batch testing. "The OsmoPRO MAX delivers the usability, automation, and data management features sought by today's clinical laboratories," said Byron Selman, CEO of Advanced Instruments. "Advanced Instruments continues to innovate in the field of osmometry while remaining committed to the product quality and reliability that customers have experienced with our osmometers for the past 70 years." About Advanced Instruments Advanced Instruments, LLC, is a leading supplier of instrumentation for clinical, pharmaceutical, biotechnology, microbiology, and food laboratories around the world. Quality, reliability, service and support have been the company's guiding principles since our founding in 1955. Our innovative application of technology helps healthcare organizations improve the quality of care and industrial companies enhance quality and productivity. For more information, please visit aicompanies.com. Media Contact: Jon Flasher, Clinical Product Manager jon.flasher@aicompanies.com Photo - https://mma.prnasia.com/media2/2605043/Advanced_Instruments_Osmopromax.jpg?p=medium600Logo - https://mma.prnasia.com/media2/701853/Advanced_Instruments_Logo.jpg?p=medium600
Biotechnology
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
